Original ArticleVisual Field and Intraocular Pressure Asymmetry in the Low-Pressure Glaucoma Treatment Study
Section snippets
Patients and Methods
Details of the Low-Pressure Glaucoma Treatment Study’s methodology have been reported.15 The null hypothesis being tested is that no differences in VF stability or progression will occur among patients randomized to treatment with brimonidine tartrate 0.2% compared with treatment with timolol maleate 0.5%. The Low-Pressure Glaucoma Treatment Study Group consisted of 13 clinical centers, and the institutional review boards at all participating centers approved the study protocol and informed
Results
One hundred ninety patients (113 women, 77 men) with a mean age of 64.9±10.7 years (range, 37–86) were enrolled in the Low-Pressure Glaucoma Treatment Study. There were 137 patients (72.1%) with bilateral VF loss and 53 patients (27.9%) with unilateral field loss. Seventy-six of 190 patients (40%) were not receiving IOP-lowering medication at the time of the baseline examination. Table 1 illustrates the clinical characteristics of patients with bilateral versus unilateral VF loss. Clinical
Discussion
Contrary to prior reports,1, 2, 3, 14 our data do not demonstrate a relationship between IOP asymmetry and VF asymmetry in LPG. Several factors are worthy of careful consideration to reconcile the Low-Pressure Glaucoma Treatment Study results with prior reports, including differences in study design, patient population, and analysis methods. Prior retrospective studies evaluated nonconsecutive patients, many of whom had both kinetic and static perimetries. As a prospective clinical trial, the
References (19)
- et al.
Unequal intraocular pressure and its relation to asymmetric visual field defects in low-tension glaucoma
Ophthalmology
(1989) - et al.
Pressure-dependent neuroretinal rim loss in normal-pressure glaucoma
Am J Ophthalmol
(1998) - et al.
Risk factors for progression of visual field abnormalities in normal-tension glaucoma
Am J Ophthalmol
(2001) - et al.
Central corneal thickness in the Ocular Hypertension Treatment Study (OHTS)
Ophthalmology
(2001) - et al.
Ambulatory blood pressure monitoring in glaucoma: the nocturnal dip
Ophthalmology
(1995) - et al.
Blood-cell velocity in the nailfold capillaries of patients with normal-tension and high-tension glaucoma
Am J Ophthalmol
(1991) - et al.
Factors that predict the benefit of lowering intraocular pressure in normal tension glaucoma
Am J Ophthalmol
(2003) - et al.
Frequency of asymmetric visual field defects in normal-tension and high-tension glaucoma
Ophthalmology
(1998) - et al.
The Low-Pressure Glaucoma Treatment Study (LoGTS)Study design and baseline characteristics of enrolled patients
Ophthalmology
(2005)
Cited by (60)
Lateral thinking – Interocular symmetry and asymmetry in neurovascular patterning, in health and disease
2017, Progress in Retinal and Eye ResearchCitation Excerpt :In fact, it is the emergence of asymmetry between the eyes that alerts the ophthalmologist to the possibility of glaucoma. Interocular differences in IOP (Cartwright and Anderson, 1988; Levine et al., 2006; Williams et al., 2013), optic disc characteristics (Armaly, 1969; Ong et al., 1999), OCT measurements of cpRNFL and macular thickness (Gugleta et al., 1999; Sullivan-Mee et al., 2013), and visual field sensitivity (Greenfield et al., 2007; Levine et al., 2006) are all features that raise suspicion of glaucoma. Indeed an interocular difference in cup-disc ratio of more than 0.2 has long been quoted as a diagnostic criterion for glaucoma (Armaly, 1969).
Advance in the pathogenesis and treatment of normal-tension glaucoma
2015, Progress in Brain ResearchNew perspectives on target intraocular pressure
2014, Survey of OphthalmologyNocturnal systemic hypotension increases the risk of glaucoma progression
2014, OphthalmologyRisk factors for optic disc hemorrhage in the low-pressure glaucoma treatment study
2014, American Journal of OphthalmologyCitation Excerpt :Of 193 patients assessed for eligibility in the Low-Pressure Glaucoma Treatment Study, 178 were randomized to treatment with either timolol or brimonidine. The characteristics of the study population have been described in detail elsewhere.12–15 Of those, 253 eyes of 127 subjects (mean age, 64.7 ± 10.9 years; women, 58%; European ancestry, 71%) met the inclusion and exclusion criteria for this study (at least 16 months of follow-up) and were followed up, on average, for 40.6 ± 12 months.
Manuscript no. 2006-227.
None of the authors has any financial interest in drugs or devices described in the article.
Supported by Allergan, Inc., Irvine, California (unrestricted grant to Low-Pressure Glaucoma Study Group); the Steven and Shelley Einhorn Research Fund of the New York Glaucoma Research Institute, New York, New York; and the Chicago Center for Vision Research, Chicago, Illinois.